Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Amyloid. 2022 Jan 27;29(2):71–78. doi: 10.1080/13506129.2021.2000388

Table 2:

Reason for diflunisal discontinuation

Subject ID Diflunisal duration of treatment (years) Reason for discontinuation
01 5.8 Reduction in creatinine clearance
02 0.4 Fatigue
03 1.0 Reduction in creatinine clearance
04 8.4 Enrollment in another clinical trial
05 4.8 Reduction in creatinine clearance
06 2.8 Gastrointestinal bleeding
07 5.0 Enrollment in another clinical trial
08 2.5 Initiation of systemic anticoagulation*
09 1.6 Reduction in creatinine clearance
10 0.8 Reduction in creatinine clearance
11 3.0 Reduction in creatinine clearance
12 3.0 Reduction in creatinine clearance
13 0.1 Volume overload
14 2.9 Initiation of systemic anticoagulation*
*

Diflunisal was discontinued at the discretion of the treating physician to reduce the risk of bleeding with initiation of systemic anticoagulation.